<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">BM2 of IBV is a functional homolog of AM2 but shares little sequence identity (Wanitchang 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR105">2016</xref>; Mandala 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR70">2019</xref>), and most mAbs targeting M2e are IAV-wide. Despite a mAb AS2 that recognizes the conservative N-terminus of M2 (amino acids 2â€“10) has been identified to possess neutralizing activity against both IAV and IBV 
 <italic>in vitro</italic> (Liu 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR66">2003</xref>), no evidence showed that immunity with current universal influenza vaccine candidates based on M2e of IAV can suppress IBV replication (Mezhenskaya 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR75">2019</xref>).
</p>
